{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:59:58Z","timestamp":1792601998885,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2007,5,1]],"date-time":"2007-05-01T00:00:00Z","timestamp":1177977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1016\/j.cca.2007.01.017","type":"journal-article","created":{"date-parts":[[2007,1,26]],"date-time":"2007-01-26T17:43:38Z","timestamp":1169833418000},"page":"217-221","source":"Crossref","is-referenced-by-count":29,"title":["Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantation"],"prefix":"10.1016","volume":"380","author":[{"given":"GholamAli","family":"Khoschsorur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Fruehwirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sieglinde","family":"Zelzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Stettin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Halwachs-Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2007.01.017_bib1","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.cca.2007.01.017_bib2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.cca.2007.01.017_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00007","article-title":"SDZ RAD, a new rapamycin derivative: synergism with cyclosporine","volume":"64","author":"Schuurman","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.cca.2007.01.017_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.cca.2007.01.017_bib5","first-page":"1220","article-title":"Everolimus","volume":"2","author":"Dumont","year":"2001","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.cca.2007.01.017_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cca.2007.01.017_bib7","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1046\/j.1365-2125.1999.00085.x","article-title":"Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients","volume":"48","author":"Neumayer","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cca.2007.01.017_bib8","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/00007890-199910270-00007","article-title":"A phase I study of a 4-week course of SDZ-RAD(RAD) in quiescent cyclosporine-prednisonetreated renal transplant recipients","volume":"68","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.cca.2007.01.017_bib9","doi-asserted-by":"crossref","first-page":"B101","DOI":"10.1016\/S0149-2918(00)89027-X","article-title":"Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus","volume":"22","author":"MacDonald","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.cca.2007.01.017_bib10","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00007691-200002000-00006","article-title":"Pharmacokinetics and metabolism of sirolimus","volume":"22","author":"Gallant-Haidner","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cca.2007.01.017_bib11","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0041-1345(98)00587-9","article-title":"Chemical modification of rapamycin: the discovery of SDZ RAD","volume":"30","author":"Sedrani","year":"1998","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cca.2007.01.017_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.112969","article-title":"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine","volume":"69","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cca.2007.01.017_bib13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/00003088-200140080-00002","article-title":"Clinical pharmacokinetics of sirolimus","volume":"40","author":"Mahalati","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cca.2007.01.017_bib14","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1053-2498(02)01221-4","article-title":"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure","volume":"22","author":"Kovarik","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.cca.2007.01.017_bib15","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0149-2918(02)85038-X","article-title":"Therapeutic drug monitoring of immunosuppressant in clinical practice","volume":"24","author":"Kahan","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.cca.2007.01.017_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00007890-200003150-00011","article-title":"Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation","volume":"69","author":"Schuurman","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.cca.2007.01.017_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-3565(24)39073-1","article-title":"Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine","volume":"294","author":"Serkova","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cca.2007.01.017_bib18","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0041-1345(00)02116-3","article-title":"Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD","volume":"33","author":"Jacobsen","year":"2001","journal-title":"Transplant Proc"},{"key":"10.1016\/j.cca.2007.01.017_bib19","first-page":"R98","article-title":"Electrospray ionization and collisional induced dissociation of RAD001 and related compounds and structural characterization of RAD001 metabolites by nano-spray and micro liquid chromatography mass spectrometry","author":"B\u00f6rnsen","year":"2001","journal-title":"Novartis Inter Rep"},{"key":"10.1016\/j.cca.2007.01.017_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1358\/dot.2004.40.2.799422","article-title":"Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction","volume":"40","author":"Kovarik","year":"2004","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.cca.2007.01.017_bib21","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S1044-0305(98)00105-6","article-title":"Structural elucidation by electrospray mass spectrometry: an approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD","volume":"9","author":"Vidal","year":"1998","journal-title":"J Am Soc Mass Spectrom"},{"key":"10.1016\/j.cca.2007.01.017_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1046\/j.1365-2125.2000.00293.x","article-title":"Pharmacokinetics of SDZ RAD and cyclosporine including their metabolites in seven kidney graft patients after the first dose of SDZ RAD","volume":"50","author":"Kirchner","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cca.2007.01.017_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/00007691-199902000-00018","article-title":"LC\/ESI-MS allows simultaneous and specific quantification of SDZ RAD and cyclosporine, including groups of their metabolites in human blood","volume":"21","author":"Kirchner","year":"1999","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cca.2007.01.017_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jchromb.2004.02.040","article-title":"Simultaneous determination of four immunosuppressants by means of high speed and robust on-line solid phase extraction\u2013high performance liquid chromatography\u2013tandem mass spectrometry","volume":"805","author":"Koal","year":"2004","journal-title":"J Chromatogr, B, Biomed Sci Appl"},{"key":"10.1016\/j.cca.2007.01.017_bib25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cccn.2004.03.017","article-title":"Rapid simultaneous quantification of immunosuppressants in transplant patients by turbulent flow chromatography combined with tandem mass spectrometry","volume":"346","author":"Ceglarek","year":"2004","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2007.01.017_bib26","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/clinchem\/48.6.955","article-title":"Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus, and cyclosporin A","volume":"48","author":"Streit","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2007.01.017_bib27","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1373\/clinchem.2005.051151","article-title":"Simultaneous measurement of sirolimus and everolimus in whole blood by high-performance liquid chromatography with ultraviolet detection","volume":"9","author":"Khoschsorur","year":"2005","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2007.01.017_bib28","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.cca.2005.07.019","article-title":"Simultaneous determination of everolimus and cyclosporine concentrations by HPLC with ultraviolet detection","volume":"364","author":"Baldelli","year":"2006","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2007.01.017_bib29","first-page":"709","article-title":"A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, part I","volume":"21","author":"Passing","year":"1983","journal-title":"J Clin Chem Clin Biochem"},{"key":"10.1016\/j.cca.2007.01.017_bib30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2007.01.017_bib31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.clinbiochem.2006.03.019","article-title":"Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients","volume":"39","author":"Salm","year":"2006","journal-title":"Clin Biochem"},{"key":"10.1016\/j.cca.2007.01.017_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00007691-200504000-00140","article-title":"Cross-reactivity of the major everolimus hydroxy metabolites with the innofluor certican immunoassay for clinical Tdm of everolimus","volume":"27","author":"Strom","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.cca.2007.01.017_bib33","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1515\/DMDI.1997.14.1.5","article-title":"Monitoring new immunosuppressive agent. Are the methods adequate?","volume":"14","author":"Holt","year":"1997","journal-title":"Drug Metab Drug Interac"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898107000290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898107000290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T06:19:51Z","timestamp":1736749191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898107000290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":33,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["S0009898107000290"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2007.01.017","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}